Healthcare · Pharmaceuticals · Market Entry Execution
Competitive Market Entry Strategy for Eye Care Pharmaceuticals
A pharmaceutical company with an ophthalmology portfolio facing intense competition, pricing pressure, and fragmented distribution. They needed more than a market assessment – they needed a strategy they could execute.
The Situation
Success in eye care requires more than product availability.
A pharmaceutical company aimed to expand its ophthalmology portfolio in the eye care pharmaceuticals market but faced intense competition from established brands, pricing pressures that risked margin erosion, and fragmented distribution channels with complex tender-driven procurement.
The client needed a differentiated, execution-ready market entry strategy – not a market attractiveness report, but a clear plan covering positioning, channels, pricing, and the partner ecosystem needed to actually win in this environment.
Engagement at a glance
Sector
Pharmaceuticals · Eye Care · Ophthalmology
Service
Market Entry Execution · Feasibility & TEV
Focus
Differentiated positioning, channel strategy, partner development
Five structural barriers to entry – all requiring different solutions.
Strong incumbent competition
Established pharmaceutical brands with long-standing physician relationships, distribution agreements, and brand recognition in specialist channels.
Commoditisation & margin erosion risk
Without clear clinical or service differentiation, pricing competition with generics and established brands would erode margins before the product achieved meaningful market presence.
Complex distribution & tender dynamics
Eye care pharmaceutical procurement spans private hospitals, specialist clinics, pharmacy chains, and government tenders – each with different requirements, decision timelines, and channel economics.
Physician adoption & clinical trust
Ophthalmologists have strong existing prescribing habits. Building clinical trust for a new or expanded portfolio requires targeted medical engagement – not just channel distribution.
Competitive pressure converted into a scalable growth strategy.
Competitive benchmarking & whitespace identification
Mapped the competitive landscape across segment, price point, physician engagement model, and channel presence – identifying the whitespace where the client could enter with a credible differentiated position rather than competing head-on with incumbents.
Value-based positioning & clinical differentiation
Rather than competing on price, a value-based positioning strategy was designed around clinical outcomes, formulation advantages, and service differentiation – giving physicians a reason to prescribe and payers a reason to list beyond unit cost.
Channel-specific commercial & pricing model
Designed pricing structures and commercial terms for each channel – private hospitals, specialist clinics, pharmacy chains, and government tenders – with margin guardrails that protected profitability even under tender negotiation pressure.
Partner ecosystem & phased execution roadmap
Identified and structured the right distribution and medical engagement partners, with a phased execution roadmap and financial model that gave leadership clear visibility into capital requirements, expected returns, and key milestones.
Competitive positioning secured. Margins protected. Growth roadmap in hand.
Positioning
Clear competitive differentiation & segment priority
Pricing
Margin-protected & scalable commercial model
Partners
Strong distribution & medical engagement ecosystem
Strategy
Capital-efficient entry with execution clarity
Expanding a pharma portfolio into a new market?
We've run market entry mandates across pharma, medtech, and healthcare across GCC, SEA, and Europe. Talk to us.